Merck & Co., Inc.
MRK
Rank in Stocks
#39
Merck & Co., Inc. is a global healthcare leader with operations spanning two... Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Share Price
$145.90
Last synced: 2026-10-16
Market Cap
$359.96B
Change (1 day)
0.16%
Change (1 year)
72.07%
Country
US
Trade Merck & Co., Inc. (MRK)
Category
Healthcare
EPS for Merck & Co., Inc. (MRK)
EPS as of June 2026 TTM: $1.26
According to Merck & Co., Inc. latest financial reports and stock price the company's current EPS (TTM) is $1.26. At the end of 2024 the company had a EPS of $6.76 an increase over its 2023 EPS that were of $0.14.
EPS history for Merck & Co., Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $1.26 | -82.69% |
| 2025 | $7.28 | 7.69% |
| 2024 | $6.76 | 4,728.57% |
| 2023 | $0.14 | -97.56% |
| 2022 | $5.73 | 11.05% |
| 2021 | $5.16 | 84.95% |
| 2020 | $2.79 | -27.34% |
| 2019 | $3.84 | 60.00% |
| 2018 | $2.40 | 152.63% |
| 2017 | $0.95 | -54.11% |
| 2016 | $2.07 | 29.38% |
| 2015 | $1.60 | -61.90% |
| 2014 | $4.20 | 180.00% |
| 2013 | $1.50 | -31.82% |
| 2012 | $2.20 | 6.80% |
| 2011 | $2.06 | 635.71% |
| 2010 | $0.28 | -93.25% |
| 2009 | $4.15 | 13.70% |
| 2008 | $3.65 | -450.96% |
| 2007 | $-1.04 | -150.98% |
| 2006 | $2.04 | -3.32% |
| 2005 | $2.11 | -19.77% |
| 2004 | $2.63 | -11.45% |
| 2003 | $2.97 | -6.31% |
| 2002 | $3.17 | -0.31% |
| 2001 | $3.18 | 7.43% |
| 2000 | $2.96 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $29.89 | 2,272.22% |
US
|
|
| $6.60 | 423.81% |
US
|
|
| $3.55 | 181.75% |
US
|
|
| $20.39 | 1,518.17% |
CH
|
|
| $7.19 | 470.63% |
CH
|
